|
Recent Developments |
|
16-JUN-17
Almost all drugs manufactured by Ipca Laboratories at its facilities at Pithampur, Silvassa and Ratlam have been banned from the US market by US Food and Drug Administration (USFDA).
11-AUG-16
Ipca Laboratories announced a sharp rise in standalone net profit for the quarter ended June 2016. During the quarter, the profit of the company rose 2.27 times to Rs 475.70 million from Rs 209.20 million in the same quarter previous year.
08... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Mar-2021 (12) | 31-Mar-2020 (12) | 31-Mar-2019 (12) | | Net sales | 51391.60 | 43674.30 | 36331.50 | | Other Income | 622.40 | 646.90 | 545.90 | | Total Income | 52014.00 | 44321.20 | 36877.40 | | Cost of goods sold | -38214.40 | -36471.50 | -31303.50 | | OPBDIT | 90228.40 | 80792.70 | 68180.90 | | PAT | 11407.70 | 6524.60 | 4549.10 | | Gross Block | - | - | - | | Equity capital | 0.00 | 0.00 | 0.00 | | EPS (Rs.) | 0.00 | 0.00 | 0.00 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | NA | NA | NA | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 173.5 | 182.3 | 184.9 | | Net margin (% of OI) | 21.9 | 14.7 | 12.3 |
|
|
Detailed Financials
|
|
|
|
|
